Roivant Sciences Ltd. $ROIV Shares Bought by New York State Common Retirement Fund

New York State Common Retirement Fund lifted its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 25.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 229,037 shares of the company’s stock after acquiring an additional 46,344 shares during the quarter. New York State Common Retirement Fund’s holdings in Roivant Sciences were worth $3,465,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in ROIV. CWM LLC boosted its stake in Roivant Sciences by 44.6% during the 2nd quarter. CWM LLC now owns 2,984 shares of the company’s stock valued at $34,000 after purchasing an additional 920 shares in the last quarter. Osaic Holdings Inc. boosted its stake in Roivant Sciences by 204.2% during the second quarter. Osaic Holdings Inc. now owns 5,783 shares of the company’s stock valued at $65,000 after buying an additional 3,882 shares in the last quarter. Rossby Financial LCC acquired a new position in Roivant Sciences during the second quarter worth about $113,000. Orion Porfolio Solutions LLC bought a new stake in Roivant Sciences in the second quarter worth about $117,000. Finally, Russell Investments Group Ltd. lifted its holdings in Roivant Sciences by 149.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 11,467 shares of the company’s stock valued at $129,000 after acquiring an additional 6,879 shares during the last quarter. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Roivant Sciences

In related news, Director Daniel Allen Gold sold 1,300,000 shares of the company’s stock in a transaction on Wednesday, November 19th. The shares were sold at an average price of $20.23, for a total value of $26,299,000.00. Following the completion of the sale, the director directly owned 18,047,727 shares in the company, valued at approximately $365,105,517.21. This represents a 6.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Richard Pulik sold 406,731 shares of the stock in a transaction on Tuesday, December 23rd. The stock was sold at an average price of $22.43, for a total transaction of $9,122,976.33. Following the transaction, the chief financial officer directly owned 239,413 shares in the company, valued at $5,370,033.59. The trade was a 62.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 12,132,392 shares of company stock worth $262,349,645 in the last ninety days. Company insiders own 10.80% of the company’s stock.

Key Roivant Sciences News

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Positive Phase 2 BEACON results for brepocitinib in cutaneous sarcoidosis — the first industry‑sponsored, placebo‑controlled positive readout in this indication, which strengthens Roivant’s dermatology franchise and is the primary catalyst behind the stock move today. Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis
• Positive Sentiment: Pipeline progress: Pulmovant (a Roivant company) completed enrollment in the Phase 2 PHocus study of mosliciguat for PH‑ILD, reducing near‑term execution risk on that program and supporting long‑term value of Roivant’s portfolio. Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study
• Neutral Sentiment: Roivant filed Q3 results and held an earnings call — investors should review the call transcript and slide deck for management commentary on milestones, cash runway, and timelines for upcoming readouts that could drive future moves. Roivant Sciences Ltd. (ROIV) Q3 2025 Earnings Call Transcript
• Negative Sentiment: Mixed/weak near‑term financials: the quarter showed a loss and revenue below some analyst expectations (company reported low single‑digit millions in revenue), which creates short‑term earnings pressure despite the clinical wins; watch guidance and cash burn commentary. Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates

Roivant Sciences Stock Performance

Shares of ROIV opened at $25.86 on Friday. The firm has a market cap of $17.99 billion, a PE ratio of -22.10 and a beta of 1.22. The firm’s 50 day moving average price is $22.07 and its 200 day moving average price is $17.81. Roivant Sciences Ltd. has a twelve month low of $8.73 and a twelve month high of $25.95.

Analyst Ratings Changes

Several analysts recently commented on the stock. Leerink Partners increased their target price on shares of Roivant Sciences from $29.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. Guggenheim reiterated a “buy” rating and set a $28.00 price objective on shares of Roivant Sciences in a research report on Thursday, December 18th. Wall Street Zen upgraded Roivant Sciences from a “strong sell” rating to a “hold” rating in a report on Sunday, November 16th. Citigroup boosted their target price on Roivant Sciences from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. Finally, HC Wainwright increased their price target on Roivant Sciences from $23.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, December 12th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.19.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.